1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Src Tyrosine Kinase Inhibitors -Pipeline Insights, 2017


DelveInsight’s, “Src Tyrosine Kinase Inhibitors-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Src Tyrosine Kinase Inhibitors. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Src Tyrosine Kinase Inhibitors. DelveInsight’s Report also assesses the Src Tyrosine Kinase Inhibitors therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope
- The report provides competitive pipeline landscape of Src Tyrosine Kinase Inhibitors
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Src Tyrosine Kinase Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Src Tyrosine Kinase Inhibitors and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Table Of Contents

Src Tyrosine Kinase Inhibitors -Pipeline Insights, 2017
Illustrative

- Src Tyrosine Kinase Inhibitors Overview
- Src Tyrosine Kinase Inhibitors Disease Associated
- Src Tyrosine Kinase Inhibitors Pipeline Therapeutics
- Src Tyrosine Kinase Inhibitors Therapeutics under Development by Companies
- Src Tyrosine Kinase Inhibitors Filed and Phase III Products
- Comparative Analysis
- Src Tyrosine Kinase Inhibitors Phase II Products
- Comparative Analysis
- Src Tyrosine Kinase Inhibitors Phase I and IND Filed Products
- Comparative Analysis
- Src Tyrosine Kinase Inhibitors Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Src Tyrosine Kinase Inhibitors - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Src Tyrosine Kinase Inhibitors - Discontinued Products
- Src Tyrosine Kinase Inhibitors - Dormant Products
- Companies Involved in Therapeutics Development for Src Tyrosine Kinase Inhibitors
- Appendix
- Methodology
- Contact Us
- Disclaimer



List of Tables

- Number of Products under Development for Src Tyrosine Kinase Inhibitors by Therapy Area, 2017
- Number of Products under Development for Src Tyrosine Kinase Inhibitors, 2017
- Number of Products under Development by Companies
- Comparative Analysis by Filed and Phase III Products, 2017
- Comparative Analysis Phase II Products, 2017
- Comparative Analysis Phase I and IND Filed Products, 2017
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2017
- Drug Candidates Profiles
- Src Tyrosine Kinase Inhibitors Assessment by Monotherapy Products
- Src Tyrosine Kinase Inhibitors Assessment by Combination Products
- Src Tyrosine Kinase Inhibitors Assessment by Route of Administration
- Src Tyrosine Kinase Inhibitors Assessment by Stage and Route of Administration
- Src Tyrosine Kinase Inhibitors Assessment by Molecule Type
- Src Tyrosine Kinase Inhibitors Assessment by Stage and Molecule Type
- Src Tyrosine Kinase Inhibitors Therapeutics - Discontinued Products
- Src Tyrosine Kinase Inhibitors Therapeutics - Dormant Products
- Products under Development by Companies, 2017


List of Figures

- Number of Products under Development for Src Tyrosine Kinase Inhibitors by Therapy Area, 2017
- Number of Products under Development for Src Tyrosine Kinase Inhibitors, 2017
- Filed and Phase III Products, 2017
- Phase II Products, 2017
- Phase I and IND Filed Products, 2017
- Discovery and Pre-Clinical Stage Products, 2017
- Src Tyrosine Kinase Inhibitors Assessment by Monotherapy Products
- Src Tyrosine Kinase Inhibitors Assessment by Combination Products
- Src Tyrosine Kinase Inhibitors Assessment by Route of Administration
- Src Tyrosine Kinase Inhibitors Assessment by Stage and Route of Administration
- Src Tyrosine Kinase Inhibitors Assessment by Molecule Type
- Src Tyrosine Kinase Inhibitors Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

  • $ 10995
  • Industry report
  • October 2016
  • by Global Data

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. It is characterized ...

Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

  • $ 6995
  • Industry report
  • December 2016
  • by GBI Research

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations Summary Hepatitis C is a blood-borne viral infection ...


Download Unlimited Documents from Trusted Public Sources

Global Therapy Market

  • January 2017
    32 pages
  • Therapy  

    Targeted Therap...  

    Monoclonal Anti...  

  • World  

View report >

Infectious Disease Statistics and Anti-Infective Market in India - Forecast

  • January 2017
    7 pages
  • Infectious Dise...  

    Anti-Infective  

  • India  

View report >

Therapy Market in the US

  • January 2017
    7 pages
  • Therapy  

    Therapy  

  • United States  

View report >

Related Market Segments :

Therapy
Targeted Therapy

ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.